- Home
- KURA vs TRML Comparison
KURA vs TRML Comparison
Compare KURA & TRML Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KURA
- TRML
- Stock Information
- Founded
- KURA 2014
- TRML 2021
- Country
- KURA United States
- TRML United States
- Employees
- KURA N/A
- TRML N/A
- Industry
- KURA Biotechnology: Biological Products (No Diagnostic Substances)
- TRML Biotechnology: Pharmaceutical Preparations
- Sector
- KURA Health Care
- TRML Health Care
- Exchange
- KURA Nasdaq
- TRML Nasdaq
- Market Cap
- KURA 713.5M
- TRML 598.9M
- IPO Year
- KURA N/A
- TRML N/A
- Fundamental
- Price
- KURA $8.09
- TRML $47.70
- Analyst Decision
- KURA Buy
- TRML Hold
- Analyst Count
- KURA 14
- TRML 12
- Target Price
- KURA $24.45
- TRML $47.04
- AVG Volume (30 Days)
- KURA 1.7M
- TRML 1.7M
- Earning Date
- KURA 11-06-2025
- TRML 11-06-2025
- Dividend Yield
- KURA N/A
- TRML N/A
- EPS Growth
- KURA N/A
- TRML N/A
- EPS
- KURA N/A
- TRML N/A
- Revenue
- KURA $83,279,000.00
- TRML N/A
- Revenue This Year
- KURA $60.25
- TRML N/A
- Revenue Next Year
- KURA $155.10
- TRML N/A
- P/E Ratio
- KURA N/A
- TRML N/A
- Revenue Growth
- KURA N/A
- TRML N/A
- 52 Week Low
- KURA $5.41
- TRML $11.56
- 52 Week High
- KURA $21.40
- TRML $47.75
- Technical
- Relative Strength Index (RSI)
- KURA 55.99
- TRML 94.37
- Support Level
- KURA $8.09
- TRML $22.31
- Resistance Level
- KURA $8.90
- TRML $47.69
- Average True Range (ATR)
- KURA 0.51
- TRML 1.00
- MACD
- KURA -0.05
- TRML 1.93
- Stochastic Oscillator
- KURA 35.20
- TRML 99.80
About KURA Kura Oncology Inc.
Kura Oncology Inc is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company's pipeline consists of small molecule drug candidates targeting cancer signaling pathways.
About TRML Tourmaline Bio Inc.
Tourmaline Bio Inc is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune diseases. Its initial product candidate is TOUR006, a fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The anti-IL-6 and anti-IL-6 receptor (IL-6R) antibody class (IL-6 class) has over two decades of clinical and commercial experience treating over a million patients with a variety of autoimmune and inflammatory diseases.